Mortality in ischaemic stroke patients without standard modifiable risk factors: An analysis of the Riksstroke registry
- PMID: 39745075
- PMCID: PMC11694267
- DOI: 10.1177/23969873241309516
Mortality in ischaemic stroke patients without standard modifiable risk factors: An analysis of the Riksstroke registry
Abstract
Introduction: Little is known of the long-term prognosis of patients with acute ischaemic stroke in the absence of standard modifiable stroke risk factors (SMoRFs). In acute coronary syndromes, patients without modifiable risk factors have a higher mortality rate. We analysed data from the Swedish Stroke Register to determine survival of patients without SMoRFs following an ischaemic stroke.
Patients and methods: We identified adult patients with first-presentation acute ischaemic stroke between 2010 and 2020. Patients were considered to possess a SMoRF if they had one of: hypertension, diabetes, hyperlipidaemia, atrial fibrillation or an active smoking history. We compared mortality in patients with and without SMoRFs following first-presentation ischaemic stroke using cox regression models. We also assessed the combined endpoint death and dependency (mRS 3-6) at 3 months via logistic regression models.
Results: Of 152,588 patients with ischaemic stroke, hypertension (58.7%) and atrial fibrillation (27.3%) were the most common risk factors. 34,019 patients (22.3%) had no SMoRFs. After a first-presentation ischaemic stroke, patients without SMoRFs had a lower risk of death than patients with one or more SMoRFs (HR 0.58 [95% CI 0.57-0.59]). The absence of SMoRFs was associated with lower odds of death and dependency at 3 months in logistic regression models (OR 0·60 [95% CI 0.58-0.62]).
Conclusion: One in five patients with acute ischaemic stroke had no standard modifiable stroke risk factors. These patients have lower risk of death compared to patients with one or more SMoRFs.
Keywords: Stroke; death; dependency; mortality; risk factors.
Conflict of interest statement
Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: SD reports personal fees from Amgen, Boehringer Ingelheim, Medtronic, Abbot, and CSL Behring. BN reports personal fees for DSMB work for Simbec-Orion.
Figures
References
-
- O’Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 2016; 388: 761–775. - PubMed
-
- Harmsen P, Lappas G, Rosengren A, et al. Long-term risk factors for stroke: twenty-eight years of follow-up of 7457 middle-aged men in Göteborg, Sweden. Stroke 2006; 37: 1663–1667. - PubMed
-
- Håheim LL, Holme I, Hjermann I, et al. Risk factors of stroke incidence and mortality. A 12-year follow-up of the Oslo study. Stroke 1993; 24: 1484–1489. - PubMed
-
- Figtree GA, Vernon ST, Hadziosmanovic N, et al. Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. Lancet 2021; 397: 1085–1094. - PubMed
-
- Nannoni S, Scherz-Moussa Youma A, Amiguet M, et al. Acute ischaemic stroke in the absence of established vascular risk factors: patient characteristics, stroke mechanism and long-term outcome. Eur J Neurol 2021; 28: 1275–1283. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
